SCHEMBL25753458

SCHEMBL25753458

Cc1ncsc1C(=O)/C=C/c1ccc(Cl)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.55
ALDH1A1 P00352 3/20 0.55
LMNA P02545 1/20 0.55
MAOB P27338 9/20 0.52
MAOA P21397 4/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
RAF1 P04049 1/20 0.50
TP53 P04637 1/20 0.50
CYP3A4 P08684 1/20 0.50
MAPK1 P28482 1/20 0.50
BCHE P06276 1/20 0.48
CYP1A2 P05177 1/20 0.47
CXCL12 P48061 1/20 0.47
KDM4E B2RXH2 1/20 0.46
PKM P14618 1/20 0.46
USP2 O75604 1/20 0.46
NPC1 O15118 1/20 0.45
GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26248943 0.88 MAPT (0.54) MAPTALDH1A1LMNAMAOBMAOA
SCHEMBL28497749 0.87 JAK2 (0.56) MAPTALDH1A1LMNAMAOBMAOA
SCHEMBL25753656 0.86 KDM4E (0.51) MAPTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL25753449 0.85 MAPT (0.57) MAPTALDH1A1LMNAMAOBMAOA
SCHEMBL25753461 0.85 PTGS2 (0.49) MAPTALDH1A1LMNACYP3A4CYP1A2
SCHEMBL25753450 0.84 F3 (0.57) MAPTALDH1A1LMNAMAOBMAOA
SCHEMBL25753457 0.84 MAOB (0.53) MAPTALDH1A1LMNAMAOBMAOA
SCHEMBL25753466 0.83 MAPT (0.55) MAPTALDH1A1LMNASMN1; SMN2KMT2A
SCHEMBL25753464 0.82 PTGS2 (0.49) MAPTALDH1A1LMNAMAOBMAOA
SCHEMBL25753460 0.78 MAOB (0.51) MAPTALDH1A1LMNAMAOBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230277508-A1 USE OF COMPOUND AS CYP2E1 INHIBITOR Shanghai Ling Xi Biotechnology Development Co., Ltd. (CN) 2023-09-07 US disclosed
US-20230277508-A1 USE OF COMPOUND AS CYP2E1 INHIBITOR Shanghai Ling Xi Biotechnology Development Co., Ltd. (CN) 2023-09-07 US disclosed
EP-4205741-A1 USE OF COMPOUND AS CYP2E1 INHIBITOR Shanghai Ling Xi Biotechnology Development Co., Ltd. (CN) 2023-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230277508-A1 USE OF COMPOUND AS CYP2E1 INHIBITOR CYP2E1, CYP11B1, CYP27A1 MAPT 1097/4885ALDH1A1 434/4885LMNA 3301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.